<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR22">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Omuro</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Vlahovic</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Lim</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Sahebjam</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Baehring</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Cloughesy</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Voloschin</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Ramkissoon</surname>
    <given-names>SH</given-names>
   </name>
   <name>
    <surname>Ligon</surname>
    <given-names>KL</given-names>
   </name>
   <name>
    <surname>Latek</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Zwirtes</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Strauss</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Paliwal</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Harbison</surname>
    <given-names>CT</given-names>
   </name>
   <name>
    <surname>Reardon</surname>
    <given-names>DA</given-names>
   </name>
   <name>
    <surname>Sampson</surname>
    <given-names>JH</given-names>
   </name>
  </person-group>
  <article-title>Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143</article-title>
  <source>Neuro-Oncology</source>
  <year>2018</year>
  <volume>20</volume>
  <issue>5</issue>
  <fpage>674</fpage>
  <lpage>686</lpage>
  <pub-id pub-id-type="doi">10.1093/neuonc/nox208</pub-id>
  <?supplied-pmid 29106665?>
  <pub-id pub-id-type="pmid">29106665</pub-id>
 </element-citation>
</ref>
